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Abstract
Background: Previous studies showed that high dose of caffeine intake may induce some specific human
reproductive system diseases, even lead to infertility.
Objectives: In consideration of the high consumption of caffeine according to the latest population-based survey,
this review is aimed to systematically review the evidence from all controlled clinical studies of caffeine intake for
infertility.
Designs: Relevant randomized/quasi-randomized controlled trials, non-randomized clinical studies, cohort studies,
and case-control studies will be included in this review. Participants will be either those without a history of
infertility who are willing to have a baby (for prospective studies) or infertile patients with confirmed diagnosis (for
retrospective studies). Caffeine or caffeine-containing beverage will be observed as the exposure factor. The key
outcome will be the diagnosis of infertility in participants. All relevant published/unpublished or ongoing studies
will be searched from seven databases and four online systems until December 2015. Two authors will screen the
literatures and extract the data independently. Methodological quality of the included studies will be assessed by
two authors according to either Risk of Bias Assessment or Newcastle-Ottawa Scale. We will use R software to
analyze the data. Dose of caffeine will be quantified on a daily basis, and relative risk with their 95 % confidence
interval will be measured. If data permit, meta-analysis and dose-response analysis will be conducted. Summary of
findings tables will be generated using Guideline Development Tool online.
Systematic review registration: PROSPERO CRD42015015714
Keywords: Caffeine intake, Infertility, Systematic review
Background
Infertility is a disease of the reproductive system defined
by the failure to achieve a clinical pregnancy after
12 months or more of regular unprotected sexual inter-
course without a certain reason, such as breast feeding
or postpartum menorrhea [1]. Primary infertility is de-
fined as the absence of a live birth for women who de-
sire a child and have been in a union for at least 5 years,
during which they have not used any contraceptives [2].
The increase of age leads to a growth of infertility rate
[3]. Infertility may be the result of infection in the man
or woman, but often, there is no obvious underlying
cause [1]. There are many biological factors and other
reasons which may lead to infertility, including some
that can be treated by medical interventions [4].
Without a certain effective treatment, in vitro
fertilization (IVF)—which may result in approximately
30 % live birth—seems to be the first option for couples
who suffered from infertility [5]. However, high rates of
drop-out are frequently encountered in IVF treatment
due to the financial burden, which is the commonest
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cause (65 %) [6]. Furthermore, the latest evidence
showed that the consequences of infertility have greater
impact on a woman’s life and can be a lifetime crisis [7].
Caffeine is present in many drinks and foods con-
sumed during pregnancy and most notably in tea, coffee,
colas, energy drinks, and chocolate [8]. Caffeine can
have both positive and negative health effects. It may
confer a modest protective effect against some diseases
of the cardiovascular system and of the metabolism of
carbohydrates and lipids, including the various forms of
arterial cardiovascular disease, arrhythmia, heart insuffi-
ciency, diabetes, liver disease [9], and even Parkinson’s
disease [10].
For the negative effect of caffeine intake on reproduct-
ive system diseases, we only found a systematic review
[8] with observational studies that showed high dose caf-
feine intake may induce specific adverse events during
pregnancy (abortion, low birth weight, stillbirth, et al.).
Though no systematic review is concerned with the rela-
tionship between caffeine intake and infertility, many
primary studies have demonstrated that caffeine is asso-
ciated with infertility [11–14]. The effects of caffeine
consumption on delayed conception were evaluated in a
European multicenter study on risk factors of infertility,
which issued that women in the highest level of caffeine
consumption had an increase of 11 % in the time leading
to the first pregnancy. Another retrospective study also
found that nonsmokers who consumed more than
301 mg caffeine daily may have 2.65 more times chance
on delayed conception. Hence, one prospective cohort
study with 18,555 participants found that the intake of
caffeinated soft drinks (compared the highest to lowest
categories) was positively related to ovulatory disorder
infertility (risk ratio = 1.47, 95 % confidence interval
from 1.09 to 1.98).
Other epidemiologic literatures reported the effect of
lifestyle factors, which point out the potential relation-
ship between caffeine consumption and female infertility
[15–17]. Among them, one study focused on 104 healthy
women who had been attempting to become pregnant
for 3 months were interviewed about their use of caf-
feinated beverages, alcohol, and cigarettes. Daily con-
sumption of coffee was likely to be relevant to the
pregnancy rate with interviewed women [18].
Regarding the potential mechanism of the caffeine as a
risk factor for the reproductive system, one experimental
study [19] examined whether in utero and lactational ex-
posure to caffeine affects the reproductive function of
the offspring of rats and found significant (caffeine)
dose-related decreases in the body and reproductive
organ weight, seminiferous tubule diameter, and germi-
nal epithelium height of the offspring. The damage on
testicles of the experimental animals was also demon-
strated [20, 21]. Even the hormone level [22] and semen
quality [23] would be affected by caffeine exposure
which also induces adverse outcomes. In consideration
of the high caffeine intake rate in women, even in preg-
nant women, it is essential to determine the relationship
between caffeine intake and women infertility. Due to
the absence of systematic evidence of this area, we
planned to conduct this review with an evidence-based
medicine approach to investigate whether caffeine intake
is a risk factor for infertility.
Objectives
This study aims to systematically review the evidence
from any type of controlled clinical studies of caffeine
intake for human infertility.
Methods
Protocol of this review was registered at PROSPERO
international register of systematic reviews (No.
CRD42015015714) on 25 December 2014, which was
available from http://www.crd.york.ac.uk/PROSPERO/
display_record.asp?ID=CRD42015015714. However, re-
garding the purpose of this review, which is to investi-
gate the relationship between caffeine intake and
infertility, we made some revisions of the protocol and
broadened the target population and type of studies. De-
tails of the protocol are described below, and all the
amendments were pre-defined before conducting the
review.
Inclusion criteria of studies
No restriction on publication types or language. For
studies which reported in languages other than Chinese
and English, we will ask professional interpreters to do
the document translation.
Type of studies
We will include controlled clinical studies, in terms of
randomized controlled trials (RCTs), quasi-RCTs or
non-randomized clinical studies (both prospective and
retrospective), cohort studies, and case-control studies.
Type of participants
For prospective studies, participants will be women/men
without a history of infertility who are willing to have a
baby. For retrospective studies, infertile women/men
with confirmed diagnosis will be included. All the in-
cluded women should be in their childbearing age,
which means they need to be premenopausal.
Type of exposure factors
As an exposure factor, caffeine can be derived from cof-
fee, tea, cola, or other caffeine-containing beverage.
Though the caffeine is also present in many foods (such
as chocolate), it may only provide 2 % of the caffeine
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consumed according to the data from two population-
based surveys [24, 25]. Since the contribution of the
caffeine-containing food as a source of caffeine is small,
and the dose of the caffeine is difficult to count, we will
only focus on studies in which caffeine or caffeine-
containing beverage was observed as the exposure
factor.
Type of outcomes
Diagnosis of infertility or not for in participants will be
the key outcome of this review. Generally accepted diag-
nostic criteria should be mentioned in the original stud-
ies; according to which, those who were diagnosed as
infertile should have suffered from at least 12 months of
unsuccessful conception.
Search strategy
We will search PubMed, the Cochrane CENTRAL Data-
base, EMBASE, China National Knowledge Infrastruc-
ture (CNKI), VIP Database, and Chinese Biomedical
Database (CBM) from inception to December 2015. Un-
published literatures (such as conference report, disser-
tation, etc.) will be achieved through Wanfang Database
and CADTH Grey matters checklist (https://
www.cadth.ca/resources/finding-evidence/grey-matters).
Ongoing studies will also be searched through the
metaRegister of Controlled Trials (http://www.con-
trolled-trials.com), the US National Institutes of Health
Ongoing Trials Register (www.clinicaltrials.gov), and the
Australian New Zealand Clinical Trials Registry
(www.anzctr.org.au). All references of the studies in-
cluded will be hand-searched for additional relevant
reports.
We will use abstract terms, keywords, and Medical
Subject Headings (MeSH) as searching terms, including
“infertility” and “sterility” with “coffee”, “caffeinated” and
“caffeine”. Variations of caffeine, such as “coffein”, “cal-
cium caffeine”, “caffeine calcium complex”, “anhydrous
caffeine”, “cafeine”, “animine”, and “caffein” will also be
included during the literature searching.
Study selection
NoteExpress software will be used to manage records
from searching databases and do screening. Two authors
(JR and XF) will independently screen and select the eli-
gible literatures for both title/abstract and full-text
phases of the review; disagreements will be resolved by
discussion and, if needed, arbitrated by a third author
(HJC). A pre-designed screening form will be used for to
double check the eligibility of potential included trials
during this process. And the form will be pilot tested as
a sample of studies. If information to make a judgment
regarding inclusion is not provided, we will contact the
authors of the original studies. Furthermore, the study
selection process will be reported in a flow diagram as
shown in Fig. 1 (study flow chart).
Data extraction
Two authors (JR and XF) will independently extract data
on patient characteristics, exposure details, clinical out-
comes, and quality-related information. Details of data
extraction for included studies are shown in Additional
files\ 1, 2, and 3 (data extraction form). The discrepan-
cies will be resolved through consensus. Missing data
will be achieved through contacting the authors of the
original studies.
Methodological quality assessment
Two authors (HJC and JR) will independently assess the
methodological quality of included trials. Methodological
quality of analytic studies will be assessed according to
the Newcastle-Ottawa Scale (NOS) [26]. Stars were
awarded in the “representative” selection samples, “com-
parability” between groups, and “completeness” and “val-
idity” records of caffeine intake or infertility. The
methodological quality of RCTs, quasi-RCTs, or non-
randomized clinical studies will be assessed according to
the risk of bias tool described in the Cochrane Hand-
book for Systematic Reviews of Interventions [27]. Seven
elements will be assessed: random sequence generation,
allocation concealment, blinding of included partici-
pants, blinding of outcome assessors, incomplete out-
come data, selective reporting, and other biases. All
eligible studies will be included, regardless of perceived
quality.
Data analysis
We will use R software to analyze the data. If data per-
mit, dose of caffeine will be quantified on a daily basis.
Where daily consumption of the caffeine were not pre-
sented as milligrams, a serving of coffee was assumed to
contain approximately 100 mg caffeine and any other
caffeine-containing beverage (e.g., tea or cola) was as-
sumed to contain 60 mg of caffeine on average [5].
Then, dose of the caffeine is categorized according to
the daily consumption, mean or median will be used for
presenting caffeine intake for each category. For each
single study, relative risk (including odds ratio, risk ratio,
and hazard ratio) with their 95 % confidence interval will
be measured for participants who have caffeine con-
sumption compared with those who have not. Clinical
heterogeneity is determined by the consistence of char-
acteristics of participants, exposure factors (such as dose
of caffeine intake), and the outcome between studies.
Statistical heterogeneity among studies will be tested by
I2 statistic. The 95 % confidence interval of I2 will also
be calculated and reported [28]. Tau-square and its 95 %
confidence interval will also be reported to further
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detect the between-study variance [29]. Meta-analysis
will be done if there are acceptable clinical and statistical
heterogeneity (I2 < 75 %) among trials. Random effects
models which are more conservative and provide better
estimates with wider confidence intervals will be used
when conducting meta-analysis [30]. To avoid the po-
tential confounding bias, only data adjusted for the iden-
tical pre-specified confounders will be pooled in the
meta-analysis. When the detected statistical heterogen-
eity is significant (I2 > 75 %) among the relevant included
studies, we will check the potential sources of the het-
erogeneity and try to pool the data with sensitive ana-
lysis or subgroup analysis as we mentioned below. Even,
we may ignore the heterogeneity during meta-analysis
with reasonable explanation. If meta-analysis is not avail-
able due to the very significant heterogeneity among
studies which we cannot afford to ignore, forest plot will
still be shown without the pooling step, which may help
readers to get an overview of the size and effects seen in
the different studies. And based on the results from each
single study, we plan to qualitatively describe the synthe-
sis of the results. Whether the meta-analysis failed to be
carried out or be modified according to the heterogen-
eity, we will discuss the limitations and the potential im-
pact on the final results.
Subgroup meta-analysis will be conducted by factors
that may contribute to the differences in the results, in-
cluding study design (retrospective or prospective), char-
acteristics of participants (gender, age, history of
infertility), dose of caffeine intake, if data are available.
Dose-response meta-analysis will be conducted if data
permit. Sensitive analyses will be conducted to deter-
mine whether the conclusions are robust to arbitrary de-
cisions made regarding the methodological quality
(according to the ROB and NOS assessment) or the
publishing time of the studies (within 5 years or not).
Publication bias will be detected through funnel plot
when included trials are more than ten [31].
Overall quality of body of evidence: summary of findings
table
Summary of findings (SOF) tables will be generated
using the Guideline Development Tool (GDT) online
program. The SOF table evaluates the overall quality of
the body of evidence for clinical outcomes only from the
results of the meta-analysis, which will use the Grading
of Recommendations, Assessment, Development and
Evaluation (GRADE) criteria [32]. The level of the evi-
dence from randomized (or non-randomized) controlled
trials would be downgraded based on study quality limi-
tations, inconsistency of effect, imprecision, indirectness,
and potential publication bias, and the level of the evi-
dence from observational studies (including cohort study
and case-control study) would be upgraded if there are
large effects of the intervention/exposure according to
the pooling results or potential uncontrolled confound-
ing bias may weaken the true effect of the intervention/
exposure. The GRADE is designed to rate the quality of
a body of evidence and can be applied to evaluate sys-
tematic reviews and other forms of evidence.
Fig. 1 Study flow chart
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Discussion
Key points of the review
This is a protocol of a systematic review of both obser-
vational studies and interventional studies. Different
from systematic review of only randomized controlled
trials, the methods of this review would be adopted ac-
cording to the characteristics of observational studies.
Besides the difference of methods on screening litera-
tures, assessing the quality of included studies, analyzing
the data, and reporting the results, the most important
thing for observational studies is to control the con-
founders among exposure factors and risk. As a compli-
cated condition, infertility may be caused by plenty of
reasons (including the lifestyle and diet), and caffeine in-
take could be one of them. Thus, all the other factors
beside caffeine intake should be measured and reported
in the original included studies. Whether or not they
analyzed the data regarding the impact of those factors,
we will include those which meet our inclusion criteria
but only pool the data adjusted for pre-specified
confounders.
Quality control of the final review
The report of the final review will be in accordance
with both the Meta-Analysis of Observational Studies
in Epidemiology (MOOSE) [33] and the Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) checklists statement [34].
A measurement tool to assess systematic reviews
(AMSTAR) statement [35] will be employed to guide the
methodology when conducting the review to avoid po-
tential bias.
Additional files
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Additional file 3: Table S3. Data extraction form for cohort study.
(DOC 101 kb)
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